Zheng et al. reported that the most common grade 3 adverse events were radiation pneumonitis (20%) and rash (10%) in TIK combined with radiotherapy as first line treatment for patients with stage IV NSCLC harboring EGFR active mutations [18]. The gene discussed is EGFR; the disease is radiation pneumonitis.